Premature Coronary Artery Disease and Plasma Levels of Interleukins; a Systematic Scoping Review and Meta-Analysis

Mohammad Haji Aghajani1,2, Amirmohammad Toloui3, Koohyar Ahmadzadeh3, Arian Madani Neishaboori3∗, Mahmoud Yousefifard4,3†

1. Prevention of Cardiovascular Disease Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
2. Department of Cardiology, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
3. Physiology Research Center, Iran University of Medical Sciences, Tehran, Iran.
4. Pediatric Chronic Kidney Disease Research Center, Tehran University of Medical Sciences, Tehran, Iran.

Abstract: Introduction: Interleukins (ILs) can act as a predictive indicator of Premature Coronary Artery Disease (pCAD) and may be useful in screening of high-risk patients. However, there is no consensus on the relationship of serum levels of ILs and pCAD, yet. As a result, this study has been conducted in order to review the literature on the relationship between serum levels of different ILs and pCAD. Methods: Medline, Scopus, Embase, and Web of Science databases were searched until December 7th 2020. Two reviewers independently screened and summarized eligible articles. A meta-analysis was performed to assess the relationship of ILs and pCAD. Results: 12 case-control articles were included. IL-6 plasma changes do happen in pCAD patients with a standardized mean difference (SMD) of 0.51 (95% CI: 0.12-0.90; p=0.010) compared with the control group. This difference was also observed when evaluating the plasma levels of IL-1 and IL-17, with an SMD of 1.42 (95% CI: 1.11-1.73; p<0.001) and 0.59 (95% CI: 0.14-1.04; p=0.011), respectively. Meanwhile, no significant difference existed in plasma levels of IL-10 (SMD=0.26; 95% CI: -0.17-0.70; p=0.236), and IL-18 (SMD=1.44; 95% CI: -0.19-3.07; p=0.083) between pCAD patients and those in the control group. Conclusion: Low level of evidence showed that there may be a significant relationship between increased plasma levels of ILs and the occurrence of pCAD. As a result, prospective cohort studies with serial assessments of serum ILs during follow up period, focusing on controlling classical risk factors of pCAD and increase in level of ILs, should be conducted.

Keywords: Coronary artery disease; cardiovascular disease; interleukins; Prognosis; Biomarkers

Received: March 2022; Accepted: May 2022; Published online: 27 June 2022

1. Introduction

Coronary artery disease (CAD) is a condition in which buildup of atherosclerotic plaques leads to narrowing of the coronary arteries. This disease manifests in various clinical forms, including angina and myocardial infarction (MI). CAD is the leading cause of death worldwide (1, 2), having a prevalence of 6.7% (18.2 million individuals) amongst people aged 20 years or older, with one individual having an MI every 40 seconds in US (3). Given its importance and profound burden on the society, identifying its risk factors and managing them could play a key role in helping affected patients. Furthermore, coronary artery disease can occur in younger ages, which is named Premature Coronary Artery Disease (pCAD). In particular, it has a cut off age, mostly suggested to be less than 55 and 65 years for men and women, respectively (4). Although most studies suggest a low incidence rate for pCAD, it is possible that with the rise in cardiovascular risk...
factors, such as smoking and obesity, among younger population, the number of young individuals with underlying conditions that may lead to pCAD is much higher than currently estimated (5). In addition, because of the devastating effects of this disease on the more active lifestyle of young patients, and also the importance of early detection and treatment of young individuals, prompt and accurate identification of young individuals who are at the greatest risk is necessary (6). pCAD is defined as an inflammatory disease (7), and cardiovascular events are more common in patients with high circulating levels of several inflammatory markers. In this regard, treating patients based on inflammatory parameters, such as hs-C reactive protein (hs-CRP), has been proved to improve outcomes (8). On the other hand, interleukins (ILs) are a group of cytokines with important roles in the regulation of immune and inflammatory responses. Several ILs (such as IL-1 and IL-6) are major players at the downstream of vascular inflammatory cascades (9). As it has been shown in several studies, there might be a relationship between serum level of different types of ILs (IL-1, IL-6, etc.) and coronary artery diseases (10-12). Since other inflammatory cytokines such as hs-C reactive protein have been classically linked to coronary events, it is also reasonable to study the possible relationship between ILs and coronary events. Therefore, ILs can serve as a predictive indicator of pCAD and may be useful in screening of high-risk patients. However, there is no consensus on the relationship of serum levels of ILs and pCAD. As a result, this study has been conducted in order to review the literature on the relationship between serum levels of different ILs and pCAD.

2. Methods

2.1. Study design and search strategy

The current systematic review and meta-analysis is designed for the aim of investigating the changes in the plasma level of different types of ILs following a coronary artery disease in the younger population, or pCAD as previously defined. Accordingly, PICO was defined as follows: patients (P): male patients younger than 55 and female patients younger than 65 years of age, with angiographically confirmed coronary artery stenosis more than 50% in coronary vessels. Index test (I): measuring plasma level of ILs in patients. Comparison (C): comparing results of the case group (with the defined coronary artery stenosis) with those of the control group (patients without the defined coronary artery stenosis). Outcome (O): occurrence of pCAD.

For this purpose, Medline (via PubMed), Scopus, Embase, and Web of Science databases were thoroughly searched using carefully selected keywords. These keywords were selected using MeSH and Emtree vocabularies, reviewing similar articles’ relevant keywords, and with the help of experts in the field. Then, a systematic search strategy was designed based on the defined P and I and using the selected keywords. This search was initially performed for articles published until November 6th, 2020, and then updated until December 7th 2020. The search strategy in Medline database is presented in Appendix 1. In addition, a manual search was also performed in Google and Google scholar to obtain any preprints and possibly missing papers.

2.2. Selection criteria

The inclusion criteria in the present systematic review were reporting plasma levels of ILs, independently in case and control groups, and conducting the research on a population of pCAD patients, regardless of their underlying condition. The exclusion criteria consisted of not having a control group, case report studies, and review articles.

2.3. Data collection

Two reviewers independently screened titles and abstracts of the retrieved articles, for inclusion based on the inclusion criteria. Then, eligible articles were obtained and exclusion criteria were applied to select the included articles. Finally, a summary of the included articles’ data was recorded using a checklist, consisting of the following variables: first author's name, publication year, country in which the study was conducted, study design, definition of the pCAD patients, number of patients in case group, number of patients in the control group, mean age of the patients in the case group, mean age of the patients in the control group, type of the measured ILs, plasma level of the ILs in the case group, plasma level of the ILs in the control group, and the time interval between angiography and measurement of ILs levels in patients’ plasma sample. Any disagreement between the reviewers was resolved via discussion with a third reviewer.

2.4. Quality assessment

Two independent reviewers performed the quality assessments using National Heart, Lung, and Blood Institute (NHLBI) quality assessment tools for case-control studies (13). Any disagreement was resolved through discussion with a third reviewer.

2.5. Statistical analysis

All analyses were performed using STATA 14.0 statistical program. Data were recorded as mean and standard deviation (SD) in case and control groups, separately. Then using “metan” command in STATA program a standardized mean difference (SMD) was calculated for each individual study. Finally, a pooled SMD and 95% confidence interval (95% CI) was reported. Heterogeneity among studies was assessed, using I2 test. Egger’s test and funnel plot were used to assess publication bias.
3. Results

3.1. Study characteristics
The systematic search in the electronic databases yielded 622 records. 269 duplicates were eliminated and 353 articles remained. Afterwards, reviewers performed the initial screening according to the inclusion criteria, gathering 44 articles were found to be potentially eligible to enter the current study. Then, applying the exclusion criteria, the next screening process was performed, resulting in the inclusion of 12 articles (all of them had case-control design) in the present systematic review and meta-analysis (Figure 1) (14-25), three of which measured more than one type of ILs in the studied patients (14, 15, 19). IL-6 was measured in seven studies (14-17, 20, 21, 24), IL-10 was measured in four studies (14, 19, 22, 25), IL-18 was measured in three studies (14, 19, 23) and IL-1 (15) and IL-17 (18) were each measured in one study. Overall, 3098 patients with pCAD and 3711 control subjects were studied in the included articles. Among them, 2696 of the pCAD patients and 2271 of control patients were male. These studies had taken place in various countries: Pakistan (14, 19), Greece (15), India (16), South Korea (17), Turkey (18), South Africa (21), Sweden (20), Mexico (22), Australia (23), Poland (24), and China (25). Regarding the design of the included studies, seven studies were conducted prospectively (14, 15, 18, 19, 21, 24, 25) and the other five were conducted retrospectively (16, 17, 20, 22, 23). All of the included studies confirmed pCAD performing a coronary angiography. Detailed characteristics of the articles is summarized in Table 1.

3.2. Risk of bias assessment
Sample size justification, blinding of the assessors, adjustment of the results based on key confounding variables, and the use of concurrent controls were not recorded in any of the studies. Also, none of the study samples were randomly taken from their target population. Table 2 presents details of risk of bias assessment among the included studies.

3.3. Publication bias
Publication bias was assessed regarding the report of the case and control groups’ plasma levels of IL-6, IL-10 and IL-18, while IL-17 and IL-1 were separately measured in only one article each. As depicted on Figure 2, no publication bias exists regarding the assessment of IL-6 (p=0.440), IL-10 (p=0.960), and IL-18 (p=0.181) in the pCAD patients.

3.4. Meta-analysis
The differences in the plasma levels of ILs between pCAD patients and control patients were evaluated, and the results are depicted in Figure 3. It was shown that IL-6 plasma changes do happen in pCAD patients with a standardized mean difference (SMD) of 0.51 (95% CI: 0.12 to 0.90; p = 0.010) compared with the control group. This difference was also observed when evaluating the plasma levels of IL-1 and IL-17, with an SMD of 1.42 (95% CI: 1.11 to 1.73; p < 0.001) and 0.59 (95% CI: 0.14 to 1.04; p = 0.011), respectively. Meanwhile, no significant difference existed in plasma levels of IL-10 (SMD=0.26; 95% CI: -0.17 to 0.70; p =0.236), and IL-18 (SMD=1.44; 95% CI: -0.19 to 3.07; p = 0.083) between pCAD patients and the control group. However, the I2 test revealed a considerable amount of heterogeneity among the studies.

4. Discussion
The present systematic review and meta-analysis evaluated the changes of the plasma levels of different types of ILs following pCAD. For this purpose, IL plasma levels were compared between the pCAD patients and the participants in the control groups in the included studies. As mentioned above, an explicit correlation exists between the occurrence of pCAD and the plasma levels of IL-6, IL-1 and IL-17. As a result, it can be concluded that in pCAD patients, a rise in the plasma levels of the three ILs will possibly be observed. However, the heterogeneity among the studies was considerably high, making it tough to firmly conclude on the exact correlation between IL plasma levels and the occurrence of pCAD. Moreover, the existing literature regarding this subject is also controversial. For instance, Satti et al. reports that increased plasma levels of IL-6 is associated with higher risk of CAD (26), while Ghazouani et al reports no correlation between CAD and IL-6 (27), while in both studies, pCAD patients were present among the study population. Overall, these heterogeneities in the studies can be attributed to many factors. Firstly, none of the studies included in our group of eligible articles reported their results with respect to coronary risk factors, for example diabetes, lipid profile, smoking status, existence of hypertension and etc., which were present in their study populations. These risk factors could result in different amounts of change in IL plasma levels. Thus, we do recommend that in future studies, these risk factors be carefully evaluated and matched between the case and the control groups.

Secondly, the time interval between IL measurement and the occurrence of pCAD was somewhat vague in the studies. As a result, IL plasma levels could change in time following a coronary event in patients. With respect to the definitions of pCAD patient not being exactly the same between the included studies, this limitation could be overturned by adopting exactly similar definitions regarding the occurrence of pCAD and, accordingly calculating the time interval between the coronary event and the measurement of ILs plasma level. In addition, all included studies had case-control design and there were no prospective cohort studies. Therefore, the
overall level of evidence in the present meta-analysis is low.

5. Conclusion
Low level of evidence showed that there may be a significant relationship between plasma levels of ILs and the occurrence of pCAD. Since, there were no prospective cohort studies, included in the present meta-analysis, the screening value of ILs in prediction of pCAD is not clear. As a result, prospective cohort studies with serial assessments of serum ILs during follow up period, focusing on controlling classical risk factors of pCAD and increase in level of ILs, should be conducted, with respect to the mentioned limitations, to resolve this uncertainty.

6. Declarations

6.1. Acknowledgments
None.

6.2. Availability of data and materials
All data generated or analyzed during this study are included in this published article.

6.3. Authors’ contributions
Study design: MY, MHA
Performing search and designing search strategy: All authors.
Data gathering and quality assessment of included studies: KA, AMN, AT, MHA
Analysis: MY
Drafting: AMN, AT, KA, MY
Critically revised: MY and MHA

6.4. Funding and supports
Prevention of Cardiovascular Disease Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

6.5. Conflict of interest
There is no conflict of interest.

6.6. Role of the Sponsor
The Prevention of Cardiovascular Disease Research Center, Shahid Beheshti University of Medical Sciences had no role in the design and conduct of the study; collection, management, and analysis of the data.

References
1. Anthony D, George P, Eaton CB. Cardiac risk factors: environmental, sociodemographic, and behavioral cardiovascular risk factors. FP Essent. 2014;421:16-20.
2. Williams RA. Cardiovascular disease in African American women: a health care disparities issue. J Natl Med Assoc. 2009;101(6):536-40.
3. Virani SS, Alonso A, Benjamin EJ, Bittencourt MS, Callaway CW, Carson AR, et al. Heart disease and stroke statistics—2020 update: a report from the American Heart Association. Circulation. 2020;E139-E596.
4. Fihn SD, Gardin JM, Abrams J, Berra K, Blankenship JC, Dallas AP, et al. 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. J Am Coll Cardiol. 2012;60(24):e44-e164.
5. Mates J, Mademont-Soler I, Fernández-Falguares A, Sarquella-Brugada G, Cesar S, Arbelo E, et al. Sudden Cardiac Death and Copy Number Variants: What Do We Know after 10 Years of Genetic Analysis? Forensic Sci Int Genet. 2020;47:102281.
6. Angelantonio ED, Butterworth AS. Clinical Utility of Genetic Variants for Cardiovascular Risk Prediction. Circ Cardiovasc Genet. 2012;5(4):387-90.
7. Tousoulis D, Charakida M, Stefanadis C. Endothelial function and inflammation in coronary artery disease. Postgrad Med J. 2008;84(993):368-71.
8. Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto Jr AM, Kastelein JJ, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359(21):2195-207.
9. Sattar N,McCary DW, Capell H, McInnes IB. Explaining how “high-grade” systemic inflammation accelerates vascular risk in rheumatoid arthritis. Circulation. 2003;108(24):2957-63.
10. Bacchigla BC, Bacchigla AB, Usnayo MIG, Bedirian R, Singh G, Pinheiro GdRC. Interleukin 6 inhibition and coronary artery disease in a high-risk population: a prospective community-based clinical study. J Am Heart Assoc. 2017;6(3):e005038.
11. Szekely Y, Arbel Y. A review of Interleukin-1 in heart disease: where do we stand today? Cardiol Ther. 2018;7(1):25-44.
12. Wainstein MV, Mossmann M, Araujo GN, Gonçalves SC, Gravina GL, Sangalli M, et al. Elevated serum interleukin-6 is predictive of coronary artery disease in intermediate risk overweight patients referred for coronary angiography. Diabetol Metab Syndr. 2017;9(1):1-7.
13. Health NLo. Study Quality Assessment Tools| National
Heart, Lung, and Blood Institute (NHLBI) United States: National Institutes of Health; 2014 [Available from: https://www.nhlbi.nih.gov/health-topics/study-quality-assessment-tools.

14. Ansari WM, Humphries SE, Naveed AK, Khan OJ, Khan DA, Khattak EH. Effect of Coronary Artery Disease risk SNPs on serum cytokine levels and cytokine imbalance in Premature Coronary Artery Disease. Cytokine. 2019;122:154060.

15. Antoniades C, Tousoulis D, Vasiilidou C, Pitsavos C, Chrysochoou C, Panagiotakos D, et al. Genetic polymorphism on endothelial nitric oxide synthase affects endothelial activation and inflammatory response during the acute phase of myocardial infarction. J Am Coll Cardiol. 2005;46(6):1101-9.

16. Ghatge M, Sharma A, Vangala RK. Association of Y-glutamyl transferase with premature coronary artery disease. Biomed Rep. 2016;4(3):307-12.

17. Cho S, Hak Lee S, Park S, Ha Jee S, Ki Hong M, Chung N, et al. The additive value of multiple biomarkers in prediction of premature coronary artery disease. Acta Cardiol. 2015;70(2):205-10.

18. Demir B, Ünğan I, Oflar E, Khankishiyev V, Pirhan O, Demir E, et al. Elevated Serum Interleukin 17A Level in Patients with Premature Acute Coronary Syndrome. Turkiye Klinikleri Cardiovasc Sci. 2015;27(2):53-60.

19. Khan DA, Ansari WM, Khan FA. Pro/anti-inflammatory cytokines in the pathogenesis of premature coronary artery disease. J Interferon Cytokine Res. 2011;31(7):561-7.

20. Lundman P, Boquist S, Samnegard A, Bennermo M, Held C, Ericsson C-G, et al. A high-fat meal is accompanied by increased plasma interleukin-6 concentrations. Nutr Metab Cardiovasc Dis. 2007;17(3):195-202.

21. Phulukdaree A, Khan S, Ramkaran P, Govender R, Moodley D, Chuturgoon AA. The Interleukin-6-147 G/C Polymorphism Is Associated with Increased Risk of Coronary Artery Disease in Young South African Indian Men. Metab Syndr Relat Disord. 2013;11(3):205-9.

22. Posadas-Sánchez R, Angeles-Martínez J, Pérez-Hernández N, Rodríguez-Pérez JM, López-Bautista F, Flores-Dominguez C, et al. The IL-10-1082 (rs1800896) G allele is associated with a decreased risk of developing premature coronary artery disease and some IL-10 polymorphisms were associated with clinical and metabolic parameters. The GEA study. Cytokine. 2018;106:12-8.

23. Thompson SR, McCaskie PA, Beilby JP, Hung J, Jennens M, Chapman C, et al. IL18 haplotypes are associated with serum IL-18 concentrations in a population-based study and a cohort of individuals with premature coronary heart disease. Clin Chem. 2007;53(12):2078-85.

24. Pauli N, Puchalowicz K, Kuligowska A, Krzystolik A, Dziedziejko V, Safranow K, et al. Associations between IL-6 and echo-parameters in patients with early-onset coronary artery disease. Diagnostics. 2019;9(4):189.

25. Wang Y, Yu X, Wang P, Bao Z. Interleukin 10 gene-627 polymorphisms in Chinese patients with early-onset coronary heart disease. Zhonghua Yi Xue Yi Chuan Xue Za Zhi. 2005;22(6):679-81.

26. Satti HS, Hussain S, Javed Q. Association of interleukin-6 gene promoter polymorphism with coronary artery disease in Pakistani families. ScientificWorldJournal. 2013;2013:538365.

27. Ghazouani L, Abboud N, Khalifa SBH, Added F, Khalfallah AB, Nsiri B, et al. -174G>C interleukin-6 gene polymorphism in Tunisian patients with coronary artery disease. Ann Saudi Med. 2011;31(1):40-4.
Figure 1: Flow diagram of the present meta-analysis.
Figure 2: Funnel plot for the analysis of publication bias regarding the correlation between the occurrence of premature coronary artery disease and the changes in the plasma level of interleukins (ILs). No publication bias was observed for IL-6 (p=0.440), IL-10 (p=0.960) and IL-18 (p=0.181).
**Figure 3:** Forest plot for the assessment of the changes in the plasma levels of interleukins (ILs) in premature coronary artery disease (pCAD) patients compared with that of the control group. SMD: Standardized mean difference; CI: Confidence interval.

| Author            | Year | SMD (95% CI)          | % Weight |
|-------------------|------|-----------------------|----------|
| **IL-6**          |      |                       |          |
| Ansari            | 2017 | 0.53 (0.37, 0.69)     | 6.49     |
| Antoniades        | 2005 | 1.99 (1.66, 2.32)     | 6.15     |
| Cho               | 2015 | 0.19 (0.06, 0.31)     | 6.53     |
| Ghatge            | 2016 | 0.36 (0.11, 0.62)     | 6.32     |
| Ludman            | 2007 | -0.04 (-0.53, 0.45)   | 5.69     |
| Pauli             | 2019 | 0.10 (-0.24, 0.44)    | 6.13     |
| Phulukdaree       | 2013 | 0.41 (0.01, 0.81)     | 5.97     |
| Subtotal (I-squared = 94.4%, p = 0.000) | 0.51 (0.12, 0.90) | 43.27 |
| **IL-10**         |      |                       |          |
| Ansari            | 2017 | -0.09 (-0.24, 0.07)   | 6.49     |
| Khan              | 2011 | 0.23 (-0.08, 0.53)    | 6.22     |
| Posadas-Sanchez   | 2018 | 0.68 (0.59, 0.76)     | 6.56     |
| Wang              | 2005 | 0.23 (-0.01, 0.47)    | 6.35     |
| Subtotal (I-squared = 96.3%, p = 0.000) | 0.27 (-0.17, 0.70) | 25.63 |
| **IL-18**         |      |                       |          |
| Ansari            | 2017 | 2.57 (2.36, 2.78)     | 6.41     |
| Khan              | 2011 | 1.51 (1.16, 1.85)     | 6.12     |
| Thompson          | 2007 | 0.26 (0.15, 0.36)     | 6.55     |
| Subtotal (I-squared = 99.5%, p = 0.000) | 1.44 (-0.19, 3.07) | 19.09 |
| **IL-1**          |      |                       |          |
| Antoniades        | 2005 | 1.42 (1.11, 1.73)     | 6.20     |
| Subtotal (I-squared = .%, p = .) | 1.42 (1.11, 1.73) | 6.20 |
| **IL-17**         |      |                       |          |
| Demir             | 2015 | 0.59 (0.14, 1.04)     | 5.81     |
| Subtotal (I-squared = .%, p = .) | 0.59 (0.14, 1.04) | 5.81 |
| Overall (I-squared = 97.7%, p = 0.000) | 0.68 (0.37, 1.00) | 100.00 |

*NOTE: Weights are from random effects analysis.*
| Author; Year; Country | Study design | Definition of pCAD in the study | No. of patients in the case group | No. of patients in the control group | Mean age of patients in the case group | Mean age of patients in the control group | No. of males in the case group | No. of males in the control group | Type of IL | Time interval between angiography and IL measurement (hours) | IL plasma level in the case group | IL plasma level in the control group | Unit |
|----------------------|-------------|---------------------------------|----------------------------------|-------------------------------------|--------------------------------------|--------------------------------------|-------------------------------|-------------------------------|----------|--------------------------------------------------------|-----------------------------|---------------------------------|------|
| Ansari; 2017; Pakistan | Prospective | >70% stenosis in at least one coronary vessel & age<45 | 329 | 310 | 42 | 39 | 329 | 298 | IL-10 | 0 | 236.6± 42.5 | 175.6±21.8 | pg/ml |
| Antoniades; 2005; Greek | Prospective | ST Segment Elevation MI & age<49 | 58 | 205 | 48.6 | 49.7 | 58 | 180 | IL-1b | 24 | 1.37±1.41 | 0.31±0.37 | pg/ml |
| Ghatge; 2016; India | Retrospective | >70% stenosis in at least one coronary vessel & age<45 in males or age<50 in females | 93 | 120 | 41.79 | 41.78 | 93 | 93 | IL-6 | 12 | 3.66±0.19 | 2.98±0.15 | pg/ml |
| Cho; 2015; Korea | Retrospective | >50% stenosis in at least two coronary vessels & age<55 in males or age<60 in females | 414 | 503 | 49.3 | 48.6 | 414 | 414 | IL-6 | NR | 9.6±44.1 | 3.6±8.9 | pg/ml |
| Demir; 2015; Turkey | Prospective | angiography confirmed coronary artery disease & age<45 | 45 | 35 | 39.6 | 40.1 | 35 | 19 | IL-17A | 12 | 2±1.88 | 0.9±1.86 | pg/ml |
| Khan; 2011; Pakistan | Prospective | >70% stenosis in at least one coronary vessel & age<45 | 98 | 74 | 40 | 35 | 89 | 65 | IL-10 | 0 | 302.25±114.81 | 145±88.89 | pg/ml |
| Ludman; 2007; Sweden | Retrospective | Myocardial infarction and age between 45-55 | 41 | 26 | 51 | 51 | 41 | 26 | IL-6 | NR | 3.7±2.28 | 3.81±3.49 | ng/dl |
| Phulukdare; 2013; South Africa | Prospective | angiography confirmed coronary artery disease & age<45 | 41 | 61 | NR | NR | 41 | 61 | IL-6 | NR | 0.91±0.01 | 0.86±0.13 | pg/ml |
| Author; Year; Country | Study design | Definition of pCAD in the study | No. of patients in the case group | No. of patients in the control group | Mean age of patients in the case group | Mean age of patients in the control group | No. of males in the case group | No. of males in the control group | Type of IL | Time interval between angiography and IL measurement (hours) | IL plasma level in the case group | IL plasma level in the control group | Unit |
|-----------------------|-------------|--------------------------------|----------------------------------|-------------------------------------|--------------------------------------|------------------------------------------|----------------------------------|----------------------------------|----------------|--------------------------------|-------------------------------|--------------------------------|------|
| Posadas-Sanchez; 2018; Mexico | Retrospective | infarction or >50% stenosis in coronary vessel & age<55 in males and age<65 in females | 1160 | 1106 | 54 | 51 | 940 | 455 | IL-10 | NR | 1.01±0.83 | 0.53±0.55 | pg/ml |
| Thompson; 2007; Australia | Retrospective | >50% stenosis in at least one coronary vessel & age<60 | 556 | 1109 | 50 | 53 | 487 | 558 | IL-18 | NR | 366.2±156 | 327.8±146.6 | pg/ml |
| Pauli; 2019; Poland | Prospective | angiography confirmed coronary artery disease & age<55 in males and age<60 in females | 100 | 50 | 49.9 | 48 | 75 | 37 | IL-6 | 12 | 1.69±2.77 | 1.47±0.33 | pg/ml |
| Wang; 2005; China | Prospective | infarction or >50% stenosis in coronary vessel & age<55 in males and age<65 in females | 163 | 112 | 51 | 49 | 94 | 65 | IL-10 | NR | 33.28±11.26 | 30.83±10.07 | pg/ml |

pCAD: Premature Coronary Artery Disease; IL: interleukin.
Table 2: Risk of bias assessment of the included studies

| Author; Year     | Items |
|------------------|-------|
|                  | 1     | 2   | 3   | 4   | 5   | 6   | 7   | 8   | 9   | 10  | 11  | 12  |
| Ansari; 2017     | YES   | YES | NO  | YES | YES | NA  | NR  | YES | YES | NR  | NO  |
| Antoniades; 2005 | YES   | YES | NO  | YES | YES | NA  | NR  | YES | YES | NR  | NO  |
| Ghatge; 2016     | YES   | YES | NO  | YES | NR  | YES | NA  | YES | YES | NR  | NO  |
| Cho; 2015        | YES   | YES | NO  | YES | YES | NA  | NR  | YES | YES | NR  | NO  |
| Demir; 2015      | YES   | YES | NO  | YES | YES | NA  | NR  | YES | YES | NR  | NO  |
| Khan; 2011       | YES   | YES | NO  | YES | YES | NA  | NR  | YES | YES | NR  | NO  |
| Ludman; 2007     | YES   | YES | NO  | YES | YES | NA  | NR  | YES | YES | NR  | NO  |
| Phulukdaree; 2013| NR    | NO  | NO  | YES | YES | NA  | NR  | YES | YES | NR  | NO  |
| Posadas-Sanchez; 2018 | YES | YES | NO  | YES | YES | NA  | NR  | YES | YES | NR  | NO  |
| Thompson; 2007   | YES   | YES | NO  | NO  | YES | NA  | NR  | YES | YES | NR  | NO  |
| Pauli; 2019      | YES   | YES | NO  | YES | YES | YES | NR  | YES | YES | NR  | NO  |
| Wang; 2005       | YES   | YES | NO  | YES | YES | NA  | NR  | YES | YES | NR  | NO  |

NA: Not applicable; NR: Not reported. Items:
1. Was the research question or objective in this paper clearly stated and appropriate?
2. Was the study population clearly specified and defined?
3. Did the authors include a sample size justification?
4. Were controls selected or recruited from the same or similar population that gave rise to the cases (including the same timeframe)?
5. Were the definitions, inclusion and exclusion criteria, algorithms or processes used to identify or select cases and controls valid, reliable, and implemented consistently across all study participants?
6. Were the cases clearly defined and differentiated from controls?
7. If less than 100 percent of eligible cases and/or controls were selected for the study, were the cases and/or controls randomly selected from those eligible?
8. Was there use of concurrent controls?
9. Were the investigators able to confirm that the exposure/risk occurred prior to the development of the condition or event that defined a participant as a case?
10. Were the measures of exposure/risk clearly defined, valid, reliable, and implemented consistently (including the same time period) across all study participants?
11. Were the assessors of exposure/risk blinded to the case or control status of participants?
12. Were key potential confounding variables measured and adjusted statistically in the analyses? If matching was used, did the investigators account for matching during study analysis?
### Appendix 1: Medline search query

| Search terms | Terms |
|--------------|-------|
| 1. | "Coronary Artery Disease" [mh] OR "Myocardial Infarction" [mh] OR "Myocardial Ischemia" [mh] OR "Acute Coronary Syndrome" [mh] OR "Coronary Stenosis" [mh] OR "ST Elevation Myocardial Infarction" [mh] OR "Non-ST Elevated Myocardial Infarction" [mh] OR "Premature CAD"[tiab] OR Premature coronary artery disease[tiab] OR coronary artery disease[tiab] OR "Coronary Artery Disease"[tiab] OR "Coronary Artery Disease, Coronary"[tiab] OR "Coronary Artery Diseases"[tiab] OR Disease, Coronary[tiab] OR Diseases, Coronary[tiab] OR "Coronary Artery Stenosis"[tiab] OR Arteriosclerosis[tiab] OR Arteriosclerotic[tiab] OR "Atherosclerosis, Coronary"[tiab] OR Atherosclerosis[tiab] OR "Coronary Atherosclerosis"[tiab] OR "Atheroatherosclerosis, Coronary"[tiab] OR "Myocardial Infarction"[tiab] OR Infarction, Myocardial[tiab] OR "Infarctions, Myocardial"[tiab] OR "Infarcts, Myocardial"[tiab] OR "Infarcts, Myocardial"[tiab] OR "Heart Attack"[tiab] OR "Heart Attacks"[tiab] OR "Myocardial Infarction"[tiab] OR "Ischemia, Myocardial"[tiab] OR "Ischemias, Myocardial"[tiab] OR "Myocardial Ischemia"[tiab] OR "Ischemic Heart Disease"[tiab] OR "Heart Disease, Ischemic"[tiab] OR Disease, Ischemic[tiab] Heart[tiab] OR Diseases, Ischemic[tiab] Heart[tiab] OR Heart Diseases, Ischemic[tiab] Heart Diseases[tiab] OR "Acute Coronary Syndrome"[tiab] OR "Acute Coronary Syndromes"[tiab] OR "Coronary Syndrome, Acute"[tiab] OR "Coronary Syndromes"[tiab] OR Acute, Coronary[tiab] OR Syndrome, Acute[tiab] OR Syndromes, Acute[tiab] Coronary[tiab] OR "Premature heart attack"[tiab] OR Coronary Stenosis[tiab] OR Stenoses, Coronary[tiab] OR Stenosis, Coronary[tiab] OR "Coronary Artery Stenosis"[tiab] OR Artery Stenoses, Coronary[tiab] OR Artery Stenosis, Coronary[tiab] OR "Coronary Artery Stenoses"[tiab] OR Stenoses, Coronary[tiab] OR Stenosis, Coronary[tiab] OR "Coronary Artery Stenoses, Coronary"[tiab] OR "ST Segment Elevation Myocardial Infarction"[tiab] OR ST Segment Elevation Myocardial Infarction[tiab] OR "ST Elevated Myocardial Infarction"[tiab] OR "STEMI"[tiab] OR "Non-ST Elevated Myocardial Infarction"[tiab] OR "Non ST Elevated Myocardial Infarction"[tiab] OR Non-ST-Elevation Myocardial Infarction[tiab] OR "Infarction, Non-ST-Elevation Myocardial"[tiab] OR Infarctions, Non-ST-Elevation Myocardial[tiab] OR "Infarction, Non-ST-Elevation Myocardial"[tiab] OR "Acute Coronary Syndrome, Non-ST-Elevation Myocardial Infarction"[tiab] OR "Non-ST-Elevation Myocardial Infarction"[tiab] OR "Non-ST-Elevation Myocardial Infarction"[tiab] OR "Non-ST-Elevation Myocardial Infarction"[tiab] OR "Non-ST-Elevation Myocardial Infarction"[tiab] |}
Appendix 1: Medline search query

| Search terms                                                                 | 4. #1 AND #2 AND #3 |
|------------------------------------------------------------------------------|---------------------|
| Factor\(\text{tiab}\) OR Erythrocyte Burst Promoting Factor\(\text{tiab}\)  |                     |
| OR Burst-Promoting Factor, Erythrocyte\(\text{tiab}\) OR Burst Promoting    |                     |
| Factor, Erythrocyte\(\text{tiab}\) OR Colony-Stimulating Factor 2 Alpha\(  |                     |
| \(\text{tiab}\) OR Colony-Stimulating Factor, Mast-Cell\(\text{tiab}\) OR     |                     |
| Colony Stimulating Factor, Mast Cell\(\text{tiab}\) OR Colony Stimulating    |                     |
| Factor, Multipotential\(\text{tiab}\) OR Colony Stimulating Factor,        |                     |
| Multipotential\(\text{tiab}\) OR Eosinophil-Mast Cell Growth-Factor\(\text{  |                     |
| tiab}\) OR Eosinophil Mast Cell Growth Factor\(\text{tiab}\) OR Hematopoietin |                     |
| 2\(\text{tiab}\) OR P-Cell Stimulating Factor\(\text{tiab}\) OR P Cell      |                     |
| Stimulating Factor\(\text{tiab}\) OR Interleukin-33\(\text{tiab}\) OR       |                     |
| Interleukin 33\(\text{tiab}\) OR IL-33\(\text{tiab}\) OR Interleukin-4\(\text{   |                     |
| tiab}\) OR Interleukin 4\(\text{tiab}\) OR B-Cell Growth Factor-1\(\text{tiab}  |                     |
| OR B Cell Growth Factor 1\(\text{tiab}\) OR B-Cell Growth Factor-1\(\text{tiab}  |                     |
| OR B Cell Proliferating Factor\(\text{tiab}\) OR B Cell Proliferating Factor- |                     |
| 1\(\text{tiab}\) OR B Cell Stimulating Factor 1\(\text{tiab}\) OR B Cell      |                     |
| Stimulating Factor 1\(\text{tiab}\) OR B Cell Stimulatory Factor-1\(\text{tiab}  |                     |
| OR BCGF-1\(\text{tiab}\) OR BCGF-II\(\text{tiab}\) OR Differentiation Factor,  |                     |
| Eosinophil\(\text{tiab}\) OR T-Cell- Replacing Factor\(\text{tiab}\) OR T    |                     |
| Cell Replacing Factor\(\text{tiab}\) OR IL-5\(\text{tiab}\) OR IL5\(\text{tiab}  |                     |
| OR T-Cell Replacing Factor\(\text{tiab}\) OR T-Cell\(\text{tiab}\) OR B-Cell  |                     |
| Growth Factor-II\(\text{tiab}\) OR B Cell Growth Factor II\(\text{tiab}\) OR     |                     |
| Eosinophil Differentiation Factor\(\text{tiab}\) OR Interleukin-6\(\text{tiab}  |                     |
| OR Interleukin 6\(\text{tiab}\) OR IL6\(\text{tiab}\) OR B-Cell Stimulatory    |                     |
| Factor 2\(\text{tiab}\) OR B-Cell Stimulatory Factor-2\(\text{tiab}\) OR        |                     |
| Differentiation Factor-2, B-Cell\(\text{tiab}\) OR Differentiation Factor 2,  |                     |
| B Cell\(\text{tiab}\) OR B-Cell Differentiation Factor-2\(\text{tiab}\) OR B    |                     |
| Cell Differentiation Factor 2\(\text{tiab}\) OR BSF-2\(\text{tiab}\) OR         |                     |
| Hybridoma Growth Factor\(\text{tiab}\) OR Growth Factor, Hybridoma\(\text{tiab}  |                     |
| OR IFN-beta 2\(\text{tiab}\) OR Plasmacytoma Growth Factor\(\text{tiab}\) OR    |                     |
| Growth Factor, Plasmacytoma\(\text{tiab}\) OR Hepatocyte-Stimulating Factor\  |                     |
| (\text{tiab}\) OR Hepatocyte Stimulating Factor\(\text{tiab}\) OR MGI-2\(\text{tiab}  |                     |
| OR Myeloid Differentiation-Inducing Protein\(\text{tiab}\) OR                |                     |
| Differentiation-Inducing Protein, Myeloid\(\text{tiab}\) OR Myeloid Differentiation |                     |
| Inducing Protein\(\text{tiab}\) OR B Cell Differentiation Factor\(\text{tiab}\)  |                     |
| OR B Cell Differentiation Factor\(\text{tiab}\) OR Differentiation Factor, B  |                     |
| Cell\(\text{tiab}\) OR Differentiation Factor, B Cell\(\text{tiab}\) OR IL-6\(\text{  |                     |
| tiab}\) OR Interferon beta-2\(\text{tiab}\) OR Interferon beta 2\(\text{tiab}\)  |                     |
| OR Interferon\(\text{tiab}\) OR B Cell Stimulatory Factor-2\(\text{tiab}\) OR     |                     |
| B Cell Stimulatory Factor 2\(\text{tiab}\) OR Interleukin-7\(\text{tiab}\) OR    |                     |
| Interleukin 7\(\text{tiab}\) OR IL7\(\text{tiab}\) OR Lymphopoietin-1\(\text{tiab}  |                     |
| OR Lymphopoietin 1\(\text{tiab}\) OR IL-7\(\text{tiab}\) OR Interleukin-8\(\text{tiab}  |                     |
| OR IL8\(\text{tiab}\) OR Monocyte-Derived Neutrophil Chemotactic Factor\(\text{tiab}  |                     |
| OR Neutrophil Activation Factor\(\text{tiab}\) OR Neutrophil-Activating       |                     |
| Peptide, Lymphocyte-Derived\(\text{tiab}\) OR Lymphocyte-Derived Neutrophil-   |                     |
| Activating Peptide, Lymphocyte\(\text{tiab}\) OR Neutrophil Activating        |                     |
| Peptide, Monocyte\(\text{tiab}\) OR Monocyte-Activating Peptide, Monocyte\     |                     |
| Derived\(\text{tiab}\) OR Monocyte-Activating Peptide, Monocyte\(\text{tiab}\)   |                     |
| OR Alveolar Macrophage Chemotactic Factor-1\(\text{tiab}\) OR Alveolar        |                     |
| Macrophage Chemotactic Factor 1\(\text{tiab}\) OR AMCF-1\(\text{tiab}\) OR      |                     |
| Anionic Neutrophil-Activating Peptide\(\text{tiab}\) OR Anionic Neutrophil      |                     |
| Activating Peptide\(\text{tiab}\) OR Neutrophil-Activating Peptide, Anionic\   |                     |
| Peptide\(\text{tiab}\) OR Peptide, Anionic Neutrophil-Activating\(\text{tiab}\)  |                     |
| OR Chemokine CXCL8\(\text{tiab}\) OR CXCL8 Chemokine\(\text{tiab}\) OR          |                     |
| CXCL8 Chemokines\(\text{tiab}\) OR Chemotactic Factor, Macrophage-Derived\(\text{  |                     |
| tiab}\) OR Chemotactic Factor, Macrophage Derived\(\text{tiab}\) OR Macrophage-   |                     |
| Derived Chemotactic Factor\(\text{tiab}\) OR Chemotactic Factor, Neutrophil\(\text{  |                     |
| tiab}\) OR Neutrophil Chemotactic Factor\(\text{tiab}\) OR Chemotactic Factor,  |                     |
| Neutrophil, Monocyte-Derived\(\text{tiab}\) OR CXCL8 Chemokine\(\text{tiab}\) OR  |                     |
| Chemokine, CXCL8\(\text{tiab}\) OR Granulocyte Chemotactic Peptide-Interleukin-8\(  |                     |
| (\text{tiab}\) OR Chemotactic Peptide-Interleukin-8, Granulocyte\(\text{tiab}\)  |                     |
| OR Granulocyte Chemotactic Peptide-Interleukin 8\(\text{tiab}\) OR IL-8\(\text{tiab}  |                     |
| OR Interleukin-9\(\text{tiab}\) OR Interleukin 9\(\text{tiab}\) OR T-Cell Growth  |                     |
| Factor P40\(\text{tiab}\) OR T Cell Growth Factor P40\(\text{tiab}\) OR P40 T-Cell  |                     |
| Growth Factor\(\text{tiab}\) OR P40 T Cell Growth Factor\(\text{tiab}\) OR IL-9\(\text{tiab}  |                     |
| OR IL9\(\text{tiab}\)                                                          |                     |